The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Gareeva A.E.
Institute of Biochemistry and Genetics of the Ufa Federal Research Center of the Russian Academy of Sciences;
Kemerovo State University;
Russian Medical Academy of Continuing Professional Education
Pozdnyakov S.A.
Moscow Scientific and Practical Center for Narcology of the Moscow Health Department
Timerbulatov I.F.
Russian Medical Academy of Continuing Professional Education;
Usoltsev Central Clinical Psychiatric Hospital;
Russian University of Medicine
Pharmacogenomic and pharmacometabolomic biomarkers of the efficacy and safety of antidepressants: focus on selective serotonin reuptake inhibitors
Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(6): 26‑35
Views: 749
Downloaded: 5
To cite this article:
Gareeva AE, Borodina LS, Pozdnyakov SA, Timerbulatov IF. Pharmacogenomic and pharmacometabolomic biomarkers of the efficacy and safety of antidepressants: focus on selective serotonin reuptake inhibitors. S.S. Korsakov Journal of Neurology and Psychiatry.
2024;124(6):26‑35. (In Russ.)
https://doi.org/10.17116/jnevro202412406126
The efficacy and safety of psychopharmacotherapy with antidepressants is of great medical importance. The search for clinical and biological predictors for choosing the optimal psychopharmacotherapy with antidepressants is actively underway all over the world. Research is mainly devoted to searching for associations of polymorphic gene variants with the efficacy and safety of therapy. However, information about a patient’s genetic polymorphism is often insufficient to predict the efficacy and safety of a drug. Modern research on the personalization of pharmacotherapy should include, in addition to genetic, phenotypic biomarkers. This is important because genotyping, for example, cannot accurately predict the actual metabolic activity of an isoenzyme. To personalize therapy, a combination of methods is required to obtain the most complete profile of the efficacy and safety of the drug. Successful treatment of depression remains a challenge, and inter-individual differences in response to antidepressants are common. About half of patients with depressive disorders do not respond to the first attempt at antidepressant therapy. Serious side-effects of antidepressant pharmacotherapy and discontinuation of treatment due to their intolerance are associated with ineffective therapy. This review presents the results of the latest studies of «omics» biomarkers of the efficacy and safety of antidepressants.
Keywords:
Authors:
Gareeva A.E.
Institute of Biochemistry and Genetics of the Ufa Federal Research Center of the Russian Academy of Sciences;
Kemerovo State University;
Russian Medical Academy of Continuing Professional Education
Pozdnyakov S.A.
Moscow Scientific and Practical Center for Narcology of the Moscow Health Department
Timerbulatov I.F.
Russian Medical Academy of Continuing Professional Education;
Usoltsev Central Clinical Psychiatric Hospital;
Russian University of Medicine
Received:
22.01.2024
Accepted:
14.02.2024
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.